Breaking News Instant updates and real-time market news.

FPRX

Five Prime

$21.84

-0.09 (-0.41%)

, BMY

Bristol-Myers

$61.89

0.14 (0.23%)

09:02
01/08/18
01/08
09:02
01/08/18
09:02

Five Prime earns IND milestone payment under collaboration with Bristol-Myers

Five Prime Therapeutics (FPRX) announced that it has achieved a milestone for the first Investigational New Drug application to the FDA by Bristol-Myers Squibb (BMY) for a therapeutic candidate under the immune checkpoint pathway discovery collaboration between the companies. The first clinical candidate from the collaboration is a fully-human monoclonal antibody targeting TIM-3, an immune checkpoint receptor that is known to limit the duration and magnitude of T-cell responses. This first IND application triggers a $5M milestone payment to Five Prime.

FPRX

Five Prime

$21.84

-0.09 (-0.41%)

BMY

Bristol-Myers

$61.89

0.14 (0.23%)

  • 08

    Jan

  • 18

    Jan

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

FPRX Five Prime
$21.84

-0.09 (-0.41%)

11/07/17
SBSH
11/07/17
NO CHANGE
Target $65
SBSH
Buy
Citi says data puts safety of Five Prime's cabiralizumab in question
The key point of today's abstract was 43% G3-5 toxicity related to Five Prime Therapeutics' cabiralizumab, which puts the safety of the drug in question, Citi analyst Robyn Karnauskas tells investors in a research note. The analyst, who notes the data do show some durable activity, does not know at what dose the safety issues occurred. It remains unclear at this point if the activity being seen is due to checkpoint or cabiralizumab's contribution, Karnauskas writes. She models a 35% probability to the cabiralizumab program, which contributes $34 to her price target of $65. The analyst has a Buy rating on Five Prime. The stock is down 34% to $28.67.
11/07/17
JEFF
11/07/17
NO CHANGE
Target $52
JEFF
Buy
Five Prime data not as strong as expected, says Jefferies
Jefferies analyst Eun Yang says the 10% overall response rate with Five Prime Therapeutics' cabiralizumab plus Opdivo in second-line pancreatic cancer is lower than expected and the six-month disease control rate of 13%. The data are "not as strong as we like to see," but compares reasonably to chemo combo in second-line pancreatic cancer, Yang tells investors in a research note. The analyst has a Buy rating on Five Prime Therapeutics with a $52 price target. The stock in midday trading is down 34% to $28.69.
11/08/17
LEER
11/08/17
NO CHANGE
LEER
Outperform
Leerink sees Five Prime recovering some of yesterday's losses
After hosting an investor call to obtain additional information on the efficacy and safety profile of cabiralizumab in pancreatic cancer, Leerink analyst Michael Schmidt expects shares Five Prime Therapeutics (FPRX) will recover some of the losses from yesterday. The efficacy observed in yesterday's data look "quite promising," while safety looks very similar to what has been seen in Opdivo monotherapy trials historically, Schmidt tells investors in a research note. He notes that Five Prime partner Bristol-Myers (BMY) remains highly engaged in the cabiralizumab program. The analyst maintains an Outperform rating on Five Prime shares. The stock in midday trading is up 15%, or $3.85, to $29.71.
11/13/17
NOMU
11/13/17
NO CHANGE
Target $94
NOMU
Buy
Five Prime recent selloff looks unfounded, says Nomura Instinet
Nomura Instinet analyst Christopher Marai believes the cabira+nivo data has been taken out of context and that the recent selloff in shares of Five Prime Therapeutics looks unfounded. The data highlight "remarkable durable responses in patients not expected to respond," Marai tells investors in a research note. He points out that the IDO inhibitor epacadostat routinely only results in 10% benefit in overall response rate. Marai keeps a Buy rating on Five Prime with a $94 price target.
BMY Bristol-Myers
$61.89

0.14 (0.23%)

11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.

TODAY'S FREE FLY STORIES

ITRM

Iterum Therapeutics

$0.00

(0.00%)

21:29
05/24/18
05/24
21:29
05/24/18
21:29
Syndicate
Iterum Therapeutics 6.15M share IPO priced at $13.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

UPL

Ultra Petroleum

$1.90

-0.14 (-6.86%)

21:27
05/24/18
05/24
21:27
05/24/18
21:27
Downgrade
Ultra Petroleum rating change  »

Ultra Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$12.77

-2.335 (-15.46%)

, EWZ

MSCI Brazil Index

$38.16

-0.52 (-1.34%)

20:57
05/24/18
05/24
20:57
05/24/18
20:57
Periodicals
Brazil president Temer says agreement with truckers was reached, Bloomberg says »

Temer says he expects the…

PBR

Petrobras

$12.77

-2.335 (-15.46%)

EWZ

MSCI Brazil Index

$38.16

-0.52 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$82.95

0.35 (0.42%)

20:46
05/24/18
05/24
20:46
05/24/18
20:46
Recommendations
Ross Stores analyst commentary at Loop Capital »

Ross Stores price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

BMRN

BioMarin

$88.30

-0.2 (-0.23%)

20:41
05/24/18
05/24
20:41
05/24/18
20:41
Recommendations
BioMarin analyst commentary at Piper Jaffray »

BioMarin approval of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 12

    Sep

DECK

Deckers Brands

$103.63

0.8 (0.78%)

, SCVL

Shoe Carnival

$26.38

0.79 (3.09%)

20:30
05/24/18
05/24
20:30
05/24/18
20:30
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

DECK

Deckers Brands

$103.63

0.8 (0.78%)

SCVL

Shoe Carnival

$26.38

0.79 (3.09%)

CAVM

Cavium

$79.53

-0.4 (-0.50%)

DGX

Quest Diagnostics

$100.89

-0.34 (-0.34%)

BMRN

BioMarin

$88.30

-0.2 (-0.23%)

ZOES

Zoe's Kitchen

$14.48

-0.41 (-2.75%)

GPS

Gap

$32.97

1 (3.13%)

EGHT

8x8, Inc.

$22.00

0.35 (1.62%)

ADSK

Autodesk

$138.76

-0.54 (-0.39%)

ROST

Ross Stores

$82.95

0.35 (0.42%)

NTNX

Nutanix

$55.39

-0.85 (-1.51%)

SPLK

Splunk

$116.35

-0.2 (-0.17%)

VEEV

Veeva

$77.24

0.5 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 31

    May

  • 07

    Jun

  • 12

    Jun

  • 14

    Jun

  • 10

    Jul

  • 12

    Sep

FL

Foot Locker

$46.38

1.35 (3.00%)

, HIBB

Hibbett Sports

$28.95

0.6 (2.12%)

20:25
05/24/18
05/24
20:25
05/24/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FL

Foot Locker

$46.38

1.35 (3.00%)

HIBB

Hibbett Sports

$28.95

0.6 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 25

    May

SNAP

Snap

$10.59

-0.045 (-0.42%)

20:06
05/24/18
05/24
20:06
05/24/18
20:06
Periodicals
Snap's Send and Request location feature aims to boost privacy, TechCrunch says »

Snapchat is taking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

MDT

Medtronic

$86.94

1.65 (1.93%)

19:52
05/24/18
05/24
19:52
05/24/18
19:52
Recommendations
Medtronic analyst commentary at Piper Jaffray »

Medtronic price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

MRK

Merck

$59.11

-0.05 (-0.08%)

, ESALY

Eisai

$0.00

(0.00%)

19:43
05/24/18
05/24
19:43
05/24/18
19:43
Hot Stocks
Eisai, Merck provide update on sNDA for Lenvatinib in HCC »

Eisai (ESALY). and Merck…

MRK

Merck

$59.11

-0.05 (-0.08%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 10

    Sep

  • 23

    Oct

MCD

McDonald's

$162.38

0.865 (0.54%)

19:18
05/24/18
05/24
19:18
05/24/18
19:18
Periodicals
McDonald's sued by customers over unwanted cheese on burgers, Miami Herald says »

Two South Forida…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

CNI

Canadian National

$83.75

-0.4 (-0.48%)

19:18
05/24/18
05/24
19:18
05/24/18
19:18
Upgrade
Canadian National rating change at Deutsche Bank »

Canadian National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

EXR

Extra Space Storage

$95.10

1.335 (1.42%)

19:11
05/24/18
05/24
19:11
05/24/18
19:11
Hot Stocks
Extra Space Storage raises quarterly dividend by 10.3% to 86c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWP

MSCI Spain Index ETF

$32.38

-0.075 (-0.23%)

, FXE

Euro Currency Trust

$112.60

0.2 (0.18%)

19:09
05/24/18
05/24
19:09
05/24/18
19:09
Periodicals
Spain opposition planning no-confidence vote for PM Rajoy, Bloomberg reports »

Spain's Socialist…

EWP

MSCI Spain Index ETF

$32.38

-0.075 (-0.23%)

FXE

Euro Currency Trust

$112.60

0.2 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

$0.00

(0.00%)

, AAPL

Apple

$188.18

-0.18 (-0.10%)

18:48
05/24/18
05/24
18:48
05/24/18
18:48
Periodicals
Breaking Periodicals news story on Samsung, Apple »

Samsung says Apple…

SSNLF

Samsung

$0.00

(0.00%)

AAPL

Apple

$188.18

-0.18 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

XOM

Exxon Mobil

$80.26

-1.88 (-2.29%)

18:43
05/24/18
05/24
18:43
05/24/18
18:43
Periodicals
Sonatrach CEO seeks cooperation with Exxon on shale gas, Reuters says »

Algerian state energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

UAL

United Continental

$70.47

0.93 (1.34%)

18:39
05/24/18
05/24
18:39
05/24/18
18:39
Periodicals
United names former FAA chief Jane Garvey chairman, Bloomberg says »

United Continental's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 07

    Jun

  • 13

    Jun

  • 26

    Jun

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.87

-0.5 (-0.18%)

18:35
05/24/18
05/24
18:35
05/24/18
18:35
Periodicals
U.S. bill would force tech firms to reveal foreign software use, Reuters says »

Senate staff said that…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.87

-0.5 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWY

iShares MSCI South Korea Index Fund

$73.49

-0.96 (-1.29%)

, SPY

SPDR S&P 500 ETF Trust

$272.87

-0.5 (-0.18%)

18:33
05/24/18
05/24
18:33
05/24/18
18:33
Periodicals
N Korea's KCNA press expressing regret over cancelled U.S. talks, Bloomberg says »

The report cites North…

EWY

iShares MSCI South Korea Index Fund

$73.49

-0.96 (-1.29%)

SPY

SPDR S&P 500 ETF Trust

$272.87

-0.5 (-0.18%)

EWJ

iShares MSCI Japan Index Fund

$60.34

-0.37 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$326.46

0.98 (0.30%)

18:30
05/24/18
05/24
18:30
05/24/18
18:30
Periodicals
Senate Committee draft bill precludes Turkey from buying F-35s, Reuters says »

The amendment to U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

GXP

Great Plains Energy

$32.77

0.02 (0.06%)

, WR

Westar Energy

$54.59

0.35 (0.65%)

18:29
05/24/18
05/24
18:29
05/24/18
18:29
Hot Stocks
Great Plains-Westar Energy merger approved by KCC, MPSC »

Great Plains Energy (GXP)…

GXP

Great Plains Energy

$32.77

0.02 (0.06%)

WR

Westar Energy

$54.59

0.35 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$70.47

0.93 (1.34%)

18:08
05/24/18
05/24
18:08
05/24/18
18:08
Hot Stocks
Boutique Air announces codeshare partnership with United Airlines »

Boutique Air announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 07

    Jun

  • 13

    Jun

  • 26

    Jun

KRNY

Kearny Financial

$14.25

-0.1 (-0.70%)

18:05
05/24/18
05/24
18:05
05/24/18
18:05
Hot Stocks
Kearny Financial increases quarterly cash dividend to 4c per share »

Kearny Financial declared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YRD

Yirendai

$28.42

-0.33 (-1.15%)

18:02
05/24/18
05/24
18:02
05/24/18
18:02
Earnings
Yirendai reports Q1 adjusted income per ADS $1.72, consensus 99c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 30

    May

  • 10

    Sep

AAPL

Apple

$188.18

-0.18 (-0.10%)

, SSNLF

Samsung

$0.00

(0.00%)

17:59
05/24/18
05/24
17:59
05/24/18
17:59
Periodicals
Apple wins $539M award from Samsung in patent trial, Bloomberg reports »

A jury in San Jose,…

AAPL

Apple

$188.18

-0.18 (-0.10%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.